228 related articles for article (PubMed ID: 28599307)
21. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
22. Morin inhibited lung cancer cells viability, growth, and migration by suppressing miR-135b and inducing its target CCNG2.
Yao D; Cui H; Zhou S; Guo L
Tumour Biol; 2017 Oct; 39(10):1010428317712443. PubMed ID: 28975847
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
[TBL] [Abstract][Full Text] [Related]
26. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
27. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Chen L; Cao H; Feng Y
World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
[TBL] [Abstract][Full Text] [Related]
28. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Aghajani M; Mokhtarzadeh A; Aghebati-Maleki L; Mansoori B; Mohammadi A; Safaei S; Asadzadeh Z; Hajiasgharzadeh K; Khaze Shahgoli V; Baradaran B
Mol Biol Rep; 2020 May; 47(5):3691-3703. PubMed ID: 32246247
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells.
Wu J; Ji A; Wang X; Zhu Y; Yu Y; Lin Y; Liu Y; Li S; Liang Z; Xu X; Zheng X; Xie L
J Transl Med; 2015 Sep; 13():289. PubMed ID: 26337460
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
31. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer.
He C; Wang L; Zhang J; Xu H
Mol Cancer; 2017 Feb; 16(1):35. PubMed ID: 28173803
[TBL] [Abstract][Full Text] [Related]
33. DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer.
Zhao HF; Zhang ZC; Shi BK; Jiang XZ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6849-6857. PubMed ID: 31486484
[TBL] [Abstract][Full Text] [Related]
34. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
[TBL] [Abstract][Full Text] [Related]
35. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
36. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.
Wu H; Huang M; Lu M; Zhu W; Shu Y; Cao P; Liu P
Cancer Chemother Pharmacol; 2013 May; 71(5):1159-71. PubMed ID: 23423488
[TBL] [Abstract][Full Text] [Related]
37. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5.
Yang ZG; Ma XD; He ZH; Guo YX
Int Braz J Urol; 2017; 43(6):1060-1067. PubMed ID: 28727371
[TBL] [Abstract][Full Text] [Related]
38. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
39. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
40. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
